{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:38:11Z","timestamp":1792442291140,"version":"4.5.0"},"reference-count":19,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T00:00:00Z","timestamp":1734912000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Temocillin is a semi-synthetic \u03b2-lactam with a narrow spectrum but high stability against hydrolysis by \u03b2-lactamases, including AmpC. Despite its favourable properties, data regarding its clinical value in the treatment of AmpC \u03b2-lactamase-producing Enterobacterales (ABPE) infections are scarce. Most recent guidelines do not include temocillin in the therapeutic strategy for ABPE infection.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>This study investigated (i) the proportion of ABPE isolates susceptible to temocillin and (ii) the clinical outcomes of patients treated with temocillin for ABPE infections.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Materials and Methods<\/jats:title>\n                  <jats:p>This retrospective multicentre (Bordeaux and Reunion Island) study was performed in two parts. First, all the antimicrobial susceptibility test (AST) results of ABPE isolated from May 2021 to August 2023 were included in the analysis. Second, all patients who had received at least one dose of temocillin for ABPE infection between 2017 and 2023 were analysed. The electronic clinical records of these patients were reviewed to determine their treatment outcomes. Therapeutic success was defined as the absence of relapse one month after the end of temocillin treatment (3\u2005months in the case of bone and joint infection) and the absence of treatment modification following an unfavourable outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>During the microbiologic period of investigation (2021\u201323), 5166 ABPE strains were included. Of these, 4253 (82%) were susceptible to temocillin, whereas 4564 (88%) were susceptible to cefepime. After restriction to third-generation cephalosporin-resistant (3GCR) ABPE strains (n\u200a=\u200a1446), the proportion of strains susceptible to temocillin was 66% (n\u200a=\u200a1227) versus 59% (n\u200a=\u200a1092) for cefepime. Temocillin treatment was initiated in 67 patients with ABPE infection during the study period (2017\u201323). The main infections were complicated urinary tract infections (n\u200a=\u200a32, 48%) and bone and joint infections (n\u200a=\u200a15, 22%). The estimated overall success rate for patients who underwent complete follow-up was 89% (n\u200a=\u200a56\/63).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Temocillin appears to be reliable for ABPE infections. Our data showed a high therapeutic success rate. Its high tolerability, narrow spectrum and ease of administration could make temocillin a relevant alternative to cefepime, the current standard for ABPE infection.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkae449","type":"journal-article","created":{"date-parts":[[2024,12,23]],"date-time":"2024-12-23T05:21:34Z","timestamp":1734931294000},"page":"576-582","source":"Crossref","is-referenced-by-count":5,"title":["Temocillin efficacy against AmpC \u03b2-lactamase-producing Enterobacterales: a relevant alternative to cefepime?"],"prefix":"10.1093","volume":"80","author":[{"given":"Xavier","family":"Brousse","sequence":"first","affiliation":[{"name":"Infectious Diseases Unit, CHU de Bordeaux , Bordeaux, F-33000 ,","place":["France"]},{"name":"Infectious Diseases Unit, CHU de La R\u00e9union , Saint-Pierre, La R\u00e9union, 97410 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Andry","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, CHU de La R\u00e9union , Saint-Pierre, La R\u00e9union, 97410 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0043-7336","authenticated-orcid":false,"given":"Marin","family":"Lahouati","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, CHU de Bordeaux , Bordeaux, F-33000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anissa","family":"Desmoulin","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, CHU de La R\u00e9union , Saint-Pierre, La R\u00e9union, 97410 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Lehours","sequence":"additional","affiliation":[{"name":"Bacteriology Laboratory, CHU de Bordeaux , Bordeaux, F-33000 ,","place":["France"]},{"name":"Bordeaux Institute of Oncology, BRIC U1312, INSERM, University of Bordeaux , Bordeaux ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurine","family":"Rignol","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Department, CHU de Bordeaux , Bordeaux, F-33000 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Petitgas","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, CHU de La R\u00e9union , Saint-Pierre, La R\u00e9union, 97410 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2245-9632","authenticated-orcid":false,"given":"Anne-Ga\u00eblle","family":"Leroy","sequence":"additional","affiliation":[{"name":"Bacteriology Laboratory, CHU de La R\u00e9union , Saint-Pierre, La R\u00e9union, 97410 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Charroyer","sequence":"additional","affiliation":[{"name":"Infectious Diseases Unit, CHU de La R\u00e9union , Saint-Pierre, La R\u00e9union, 97410 ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,12,23]]},"reference":[{"key":"2025020223522982600_dkae449-B1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/jac\/dkn511","article-title":"Temocillin revived","volume":"63","author":"Livermore","year":"2009","journal-title":"J Antimicrob Chemother"},{"key":"2025020223522982600_dkae449-B2","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/jac\/dkl046","article-title":"In vitro activity of temocillin against extended spectrum \u03b2-lactamase-producing Escherichia coli","volume":"57","author":"Rodriguez-Villalobos","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"2025020223522982600_dkae449-B3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1093\/jac\/36.3.483","article-title":"The ability of \u03b2-lactam antibioties to select mutants with derepressed \u03b2-lactamase synthesis from Citrobacter freundii","volume":"36","author":"Stapleton","year":"1995","journal-title":"J Antimicrob Chemother"},{"key":"2025020223522982600_dkae449-B4","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.cmi.2015.05.022","article-title":"Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin","volume":"21","author":"Giske","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"2025020223522982600_dkae449-B5","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1093\/jac\/dkae072","article-title":"Impact of the phenotypic expression of temocillin resistance in Escherichia coli on temocillin efficacy in a murine peritonitis model","volume":"79","author":"Mallart","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"2025020223522982600_dkae449-B6","doi-asserted-by":"publisher","first-page":"e0035823","DOI":"10.1128\/aac.00358-23","article-title":"Temocillin resistance in the Enterobacter cloacae complex is conferred by a single point mutation in BaeS, leading to overexpression of the AcrD efflux pump","volume":"67","author":"Gu\u00e9rin","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020223522982600_dkae449-B7","volume-title":"Antibioth\u00e9rapie des Infections \u00e0 Ent\u00e9robact\u00e9ries et \u00e0 Pseudomonas aeruginosa Chez L\u2019adulte: Place des Carbap\u00e9n\u00e8mes et de Leurs Alternatives","author":"Haute Autorit\u00e9 de Sant\u00e9","year":"2023"},{"key":"2025020223522982600_dkae449-B8","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/S1473-3099(21)00407-2","article-title":"The clinical and microbiological efficacy of temocillin versus cefotaxime in adults with febrile urinary tract infection, and its effects on the intestinal microbiota: a randomised multicentre clinical trial in Sweden","volume":"22","author":"Edlund","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"2025020223522982600_dkae449-B9","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1093\/cid\/ciad428","article-title":"Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial resistant gram-negative infections","author":"Tamma","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025020223522982600_dkae449-B10","doi-asserted-by":"publisher","first-page":"dlac086","DOI":"10.1093\/jacamr\/dlac086","article-title":"Clinical and microbiological evaluation of temocillin for bloodstream infections with Enterobacterales: a Belgian single-centre retrospective study","volume":"4","author":"Oosterbos","year":"2022","journal-title":"JAC Antimicrob Resist"},{"key":"2025020223522982600_dkae449-B11","first-page":"p37","volume-title":"CASFM\/EUCAST: Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie","author":"Jehl","year":"2020"},{"key":"2025020223522982600_dkae449-B12","first-page":"1"},{"key":"2025020223522982600_dkae449-B13","doi-asserted-by":"publisher","first-page":"dlad114","DOI":"10.1093\/jacamr\/dlad114","article-title":"Impact of revised breakpoints on the categorization of susceptibility of Enterobacterales to temocillin","volume":"5","author":"Farfour","year":"2023","journal-title":"JAC Antimicrob Resist"},{"key":"2025020223522982600_dkae449-B14","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1093\/jac\/dku465","article-title":"Temocillin (6g daily) in critically ill patients: continuous infusion versus three times daily administration","volume":"70","author":"Laterre","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2025020223522982600_dkae449-B15","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1001\/jama.2023.20583","article-title":"Cefepime vs piperacillin-tazobactam in adults hospitalized with acute infection: the ACORN randomized clinical trial","volume":"330","author":"Qian","year":"2023","journal-title":"JAMA"},{"key":"2025020223522982600_dkae449-B16","doi-asserted-by":"publisher","first-page":"e0119323","DOI":"10.1128\/aac.01193-23","article-title":"Divergent genetic landscapes drive lower levels of AmpC induction and stable de-repression in Serratia marcescens compared to Enterobacter cloacae","volume":"68","author":"Lazarus","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2025020223522982600_dkae449-B17","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/cid\/ciae160","article-title":"Mutation rate of AmpC \u03b2-lactamase-producing Enterobacterales and treatment in clinical practice: a word of caution","volume":"79","author":"Maillard","year":"2024","journal-title":"Clin Infect Dis"},{"key":"2025020223522982600_dkae449-B18","first-page":"46","volume-title":"CASFM\/EUCAST: Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie","author":"Cattoir","year":"2022"},{"key":"2025020223522982600_dkae449-B19","first-page":"49","volume-title":"CASFM\/EUCAST: Soci\u00e9t\u00e9 Fran\u00e7aise de Microbiologie","author":"Cattoir","year":"2023"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/2\/576\/61258182\/dkae449.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/2\/576\/61258182\/dkae449.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,2]],"date-time":"2025-02-02T23:52:39Z","timestamp":1738540359000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/2\/576\/7930697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,23]]},"references-count":19,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,12,23]]},"published-print":{"date-parts":[[2025,2,3]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkae449","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,2]]},"published":{"date-parts":[[2024,12,23]]}}}